GCGR and type 1 diabetes mellitus: The therapeutic potential of inhibition of glucagon’s action in type 1 diabetes has been extensively investigated [22, 23], and a phase II trial to examine the effects of the glucagon receptor antagonist volagidemab was reported recently [24].